For the millions of adults living with inflammatory arthritis, the affordability and long-term sustainability of biologic therapies directly shapes whether they can access treatment. A decade-long analysis of Australia's drug reimbursement system offers one of the most detailed real-world pictures yet of how biosimilar competition reshapes pharmaceutical spending — and what that means for patient access at scale.
Analyzing PBS dispensing data from 2015 through 2025, the study quantified cumulative public savings of AU$562.3 million attributable to biosimilar entry for three TNF inhibitors: adalimumab, etanercept, and infliximab, all used in inflammatory arthritis. Etanercept biosimilars drove the largest absolute reduction — AU$341.5 million, representing a 23.7% expenditure decrease — while adalimumab biosimilars generated a comparatively modest 9.4% relative saving (AU$195.3 million), largely because biosimilar entry was delayed despite adalimumab being the highest-utilization drug in the class. Savings were concentrated in rheumatoid arthritis, with ankylosing spondylitis and psoriatic arthritis contributing smaller shares. The analysis constructed counterfactual spending models that explicitly incorporated Australia's mandatory price-reduction and price-disclosure mechanisms, making the savings estimates more rigorous than simple before-after comparisons.
This work matters beyond health economics. When biosimilars generate substantial savings within a public formulary, those funds can theoretically be redirected toward expanding access or covering newer therapies — a compounding benefit that pure cost studies rarely quantify. The adalimumab finding is particularly instructive: high market volume alone does not guarantee large biosimilar savings if regulatory or commercial factors delay competition. This mirrors patterns observed in the United States and European markets, where adalimumab biosimilar uptake lagged due to patent litigation and contracting strategies. The study is observational and population-level, so it cannot assess individual clinical outcomes or biosimilar switching rates. Still, it provides a credible, methodology-transparent benchmark that other publicly funded systems can use to model their own biosimilar policy impact — an incrementally valuable but practically significant contribution to the field.